文献速递贫血与红细胞疾病

国家肾母细胞瘤研究3-5中严重肝病:患病率、临床特征及重新引入化疗后的结局

Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes After Reintroduction of Chemotherapy.
PubMed 文献 · J Clin Oncol · 2023-06-21

该研究回顾了NWTS 3-5方案中严重肝病(SH)患者的档案,8862例中71例(0.8%)符合标准。SH中位发生时间为51天,60%接受放疗,56%为右侧肿瘤,70%初发时伴1-4级血小板减少。重新引入化疗对多数患者看似可行,5年无事件生存率89%。

要点

  • NWTS 3-5中严重肝病发生率为0.8%(71/8862),中位发生时间51天。
  • 70%患者SH初发时伴1-4级血小板减少,中位血小板计数22,000/微升。
  • 继续化疗者5年无事件生存率89%(95%CI 81-98),延迟或减量与否无显著差异。

核心结论

  • NWTS 3-5中严重肝病发生率低,常伴严重血小板减少,对多数患者谨慎重新引入化疗似乎可行。

研究设计与样本

  • 回顾性分析NWTS 3-5方案入组患者的存档病历,采用既定肝病分级标准和临床标准判定严重肝病,并对14例患者进行候选基因多态性分析。

主要发现

  • 8862例中71例(0.8%)符合严重肝病标准,中位发生时间51天(范围2-293天)。
  • 60%接受放疗,56%为右侧肿瘤,70%初发时伴1-4级血小板减少(中位22,000/微升)。
  • 69例治疗结束前发生SH且有后续治疗信息的患者中,65%延迟化疗(其中69%减量),20%未延迟继续化疗(其中57%减量),15%完全停止化疗(其中4/10死于SH)。
  • 减量患者中42%在治疗结束时恢复全量。
  • 继续化疗者5年无事件生存率89%(95%CI 81-98),延迟或减量与否无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The safety of reintroducing chemotherapy in the pediatric renal tumor setting after severe hepatopathy (SH), including sinusoidal obstruction syndrome (SOS), is uncertain. We describe the incidence, severity, outcomes, and impact on subsequent treatment for patients with SH from National Wilms Tumor Study (NWTS) protocols 3-5. PATIENTS AND METHODS: Archived charts for patients enrolled on NWTS 3-5 who met study inclusion criteria for SH by using established hepatopathy grading scales and clinical criteria were reviewed for demographics, tumor characteristics, radio- and chemotherapy details, SH-related dose modifications, and oncologic outcomes. Genomic analysis for candidate polymorphisms associated with SH was performed in 14 patients. RESULTS: Seventy-one of 8,862 patients (0.8%) met study inclusion criteria. The median time from therapy initiation to SH was 51 days (range, 2-293 days). Sixty percent received radiotherapy, and 56% had right-sided tumors. Grade 1-4 thrombocytopenia was noted in 70% at initial occurrence of SH (median 22,000/microliter). Among 69 of 71 children with SH occurring before the end of therapy (EOT) and post-SH treatment information available, chemotherapy was delayed posthepatopathy for 65% (69% of these at a reduced dose), continued without delay for 20% (57% of these at reduced dose), and stopped completely for 15% (4 of 10 of whom died of SH). Overall, 42% of patients with dose reductions achieved full dose by EOT. The five-year post-SH event-free survival for patients who continued therapy was 89% (95% CI, 81 to 98), with no significant differences by whether delay or dose reduction occurred. We identified no SH-associated pharmacogenomic polymorphism. CONCLUSION: The incidence of SH on NWTS 3-5 was low; many had associated severe thrombocytopenia. Careful reintroduction of chemotherapy appeared to be feasible for the majority of patients who developed severe chemotherapy- and/or radiotherapy-induced liver toxicity.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Oosterom N, Gooskens SLM, Renfro LA, et al. Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes After Reintroduction of Chemotherapy. J Clin Oncol. 2023. PMID: 37343199. doi:10.1200/JCO.22.02555

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。